Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBITION phase 2 total neoadjuvant therapy study in cT2 rectal cancer
jRCTs051230014Phase 2Active, not recruiting
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in rectal cancer. Primary endpoints: Pathological complete response rate and Clinical complete response rate. Started May 2023; status: active, not recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on jRCTs051230014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230014.